Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials
Authors
Scott A. Halperin (ORCID: https://orcid.org/0000-0003-0525-589X)
Christian F. Ockenhouse
Luis Barreto (ORCID: https://orcid.org/0000-0001-6264-5494)
Janis L. Breeze (ORCID: https://orcid.org/0000-0002-5458-1010)
Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials
Scott A. Halperin, Christian F. Ockenhouse, Luis Barreto, Janis L. Breeze et al.
Journal
Vaccine
Topics
Pneumonia and Respiratory Infections
article
Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials
Scott A. Halperin, Christian F. Ockenhouse, Luis Barreto, Janis L. Breeze, Jodi Feser, Nancy Hosken, Indah Andi-Lolo, Manish Sadarangani, Yuxiao Tang, Joanne M. Langley, Lingyun Ye, Sybil A. Tasker
article en
Abstract
No abstract available for this paper.
Publication Tag
VaccineVol. 75
Institutions
Dalhousie University (CA), Program for Appropriate Technology in Health (US), Golder Associates (Canada) (CA), Nova Scotia Health Authority (CA), Seattle Photonics Associates (United States) (US), Inventprise (United States) (US), BC Children's Hospital (CA)